FDA says four doses of Lilly’s diabetes drug Mounjaro will be in short supply through April

The FDA said Tuesday that shortages of three higher doses of Eli Lilly’s type 2 diabetes drug Mounjaro aren’t expected to ease until May, and another lower dose is now in short supply as well.

According to the FDA’s website, the 7.5, 10.0, 12.5, and 15.0 mg doses of Mounjaro will have “limited availability” through April due to increased demand. In February, the regulator said there would be supply issues for the three higher doses through early March.

Two doses — 2.5 mg and 5 mg — are listed as available.

In its most recent earnings report in February, Lilly said that it “has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand, which is expected to affect volume.” Mounjaro has been used off-label for weight loss by some patients. The same drug is approved as Zepbound for weight loss.

The drugmaker has taken steps to build out its manufacturing capacity, including expanding its facility in Research Triangle Park, NC, and two manufacturing sites within the LEAP Innovation Park in Indiana. It also invested $2.5 billion in a new site in Germany to build out its global injectable and device manufacturing network.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks